Background: Long-acting beta2-agonists (LABA) are recommended in asthma therapy; however, not all asthma patients respond well to LABA. We performed a systematic review on genetic variants associated with LABA response in patients with asthma.
| INTRODUC TI ON
Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment in adults and children. For patients with moderate or severe asthma poorly controlled on low-dose ICS, current treatment guidelines recommend increasing the ICS dosage or adding a long-acting beta-agonist (LABA). 1, 2 Both are effective therapies for managing asthma by controlling symptoms, improving lung function, and/or reducing exacerbations in patients with asthma. [3] [4] [5] Nevertheless, there is much variation in how patients respond to LABA. A post hoc analysis of 85 patients from two randomized controlled trials (RCTs) showed a variability of ≥70% in changes in peak expiratory flow in patients receiving salmeterol. 6 Factors including suboptimal inhalation technique, poor adherence, comorbidities, psychosocial factors, and/or continued environmental exposure to allergens or air pollution can contribute to this variation. 7 Genetic variation can also play an important role in determining LABA response. 8, 9 The contribution of genetic factors to observed differences in bronchodilator response is approximately 28.5% for short-acting beta-agonist (SABA). 10 However, in clinical practice we cannot yet predict LABA response. 11 In 2016, a report by asthma experts commissioned by the FDA warned for severe asthma exacerbations in patients treated with LABA, questioning the safety of LABA in adults and children with asthma. [12] [13] [14] A subset of 18% of the asthma patients treated with LABA had increased risk of worse asthma outcomes such as lung function decline, severe exacerbations, and even death. [15] [16] [17] Variation in the ADRB2 gene that codes for the beta2-adrenergic receptor (B2AR) is a usual suspect to predict LABA treatment outcomes, due to its central role in the working mechanism of LABA.
It contains various single nucleotide polymorphisms (SNPs), a single base pair variation that occurs at a specific position. In 1992, nine genetic variants in the ADRB2 gene were identified in patients with asthma, including rs1042713, rs1042714, and rs1800888.
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Rs1042713 is known for amino acid change ("missense mutation") in wild-type Gly16Gly by the following variants: Arg16Arg and Arg16Gly. Rs1042714 leads to an amino acid change at position 27 and encodes for three genotypes: Glu27Gln, Gln27Gln, and Glu27Glu. Both SNPs showed functional relevance in vitro 10 and were further studied to search for associations with LABA response heterogeneity. 19 There is also some evidence for functional relevance of rs1800888 at position 164 (Thr164Ile). These three SNPs reduce the degree of agonist-promoted downregulation of the B2AR expression and stimulate adenyl cyclase activity. 10 Abstract sections were screened to determine whether studies described the association of specific genetic polymorphisms with the response to LABA by two reviewers (EMAS and NMBO).
| ME THODS
After the initial selection, full-text papers were analyzed and the following data were collected: name of the author, year of publication, involved genes and SNPs (rs-numbers), study population, design, number of included patients, medication (type, dosage, duration) used, parameters to define treatment response, and study F I G U R E 1 Schematic overview of the ADRB2 gene and the ADCY9 gene and their most studied SNPs outcome. We screened review articles for additional research papers. SNPedia, 21 PharmGKB, 22 and PubMed were used to find the dbSNP reference ID numbers ("rs-numbers") when these were not reported. In case of disagreement concerning data extraction, consensus between authors was reached.
Quality assessment was performed using the STrengthening the REporting of Genetic Association Studies (STREGA) checklist (see supplemantary information E1).
23,24

| RE SULTS
We identified 151 studies in PubMed and 72 in EMBASE ( Figure 2 ).
Three additional studies 9, 25, 26 were identified through review papers. 10, 27, 28 Of all studies, 33 were pharmacogenetics studies that studied LABA response heterogeneity in asthma. Fourteen were observational, and 19 studies were clinical trials (Tables 2 and supplemantary table E2 ). Only 33.3% of the identified studies used a prospective genotype-stratified design. All studies were candidategene studies; none were genomewide association studies (GWAS). In Arg16Arg and Arg16Gly patients, there was less protection against bronchoconstriction compared to Gly16Gly after the last dose of 1-to 2-week treatment with formoterol or salmeterol. 44, 51 This was measured by methacholine and adenosine monophosphate bronchial challenges. Doses were uptitrated with 5-minute intervals until a decrease in FEV1 exceeding 20% of baseline was achieved. Arg16Arg vs 30 Arg16Gly or Gly16Gly patients). 37 Six RCTs (n = 1001), of which four were prospective, did not
| Study outcomes
show any interaction between LABA response and rs1042713 on lung function outcomes. 19, 31, 33, 43, 44 In a crossover study, 24 Gly16Gly patients received either placebo, leukotriene receptor antagonist (LTRA), or LABA as ICS add-on treatment (follow-up 6 weeks). 52 Primary outcome was provocative dose of methacholine: There was no significant difference in PD20: 
Exacerbations (three studies)
One observational study (n = 108) focused on exacerbations and reported that Arg16Arg patients had more exacerbations during daily use of SABA, but not with LABA. 25 Two post hoc RCT analyses (n = 2107 patients) studied the influence on exacerbations despite LABA treatment (eg, time to first severe exacerbation 26 and a worsening asthma event requiring oral or parenteral corticosteroids 46 ). No significant associations were found.
Patient-centered outcomes (five studies)
Five studies addressed the effect of genotyping on patient-reported outcomes. One observational study (n = 544) focused on patientreported asthma outcomes during LABA treatment and reported no evidence of an effect of B2AR variation. 40 In a pharmacogenetic RCT, salmeterol was withdrawn in 25
(total n = 67) of the included asthma patients with an Arg16Arg or
Gly16Gly genotype after a 6-week run-in period on fluticasone/ salmeterol for all patients. Only in the Gly16Gly patients, a significant decline of a.m. PEF rate was observed (−14.4 L/s, P = 0.06).
Nevertheless, LABA discontinuation led to a clinically meaningful asthma-related quality-of-life improvement in both groups. 30 Two additional studies (n = 106 Arg16Arg and Gly16Gly patients)
did not show an association between this genetic variation and variation in LABA response measured by symptom scores 31 and ACQ. 33 A post hoc RCT analysis (n = 183 patients receiving LABA and ICS) did not discover associations with nighttime awakenings. 43 
Pediatric studies
Most studies used exacerbations and patient-centered outcomes, but not lung function, as main outcome measures.
Exacerbations (six studies)
In total, 2666 children were studied in LABA pharmacogenetic studies with exacerbations as an outcome. Of these studies, five found an increased risk of exacerbations 35, 36, 48, 49 in Arg16Arg patients treated with LABA. Four were included in a meta-analysis. 45 The first pediatric studies showing an effect of Arg16 on LABA response heterogeneity were performed within BREATHE. 36, 48, 49 The association between carrying this genetic variant and LABA response was studied (n = 546, 3-22 years) in patients treated with albuterol, salmeterol, and ICS. 49 An increased hazard of exacerbations over the previous 6 months was found in Arg16Arg patients treated with salmeterol compared with Gly16Gly patients (OR 3.40, 95% CI: 1.19-3.53, P = 0.010). Three years later, a study (n = 1182)
in BREATHE was published. 48 Compared to Gly16Gly patients, (T/C), rs3729943: (C/G), Leu342Pro: (T/C), (-376 In contrast, a population-based prospective cohort study (n = 97 treated with fluticasone propionate and salmeterol) did not find effect of ADRB2 genotype on LABA treatment outcomes. 35 There was no difference in risk of asthma exacerbations or lung function decline between Arg16Arg and Gly16Gly or Gly16Arg patients. Furthermore, a three-treatment, three-period crossover RCT (n = 182, 6-17 years)
showed that Arg16Gly did not predict probability of best response to ICS, ICS plus LABA, or ICS plus montelukast defined by acute asthma exacerbations, number of asthma-control days, and FEV1 (P = 0.49). 35 In 2016, a meta-analysis focusing on the association between ADRB2 rs1042713 and LABA response was performed 45 
ADRB2 Arg16 heterozygotes (three studies)
Only three studies described results for heterozygous patients.
FEV1 decline was described for each Arg allele irrespective of ICS
or LABA use (n = 604 adults): 7.7 ± 2.5 mL/y. 38 The earlier discussed paper (n = 1182, 3-22 years) showed an increased risk of exacerba- 
| ADRB2 rs1042714 (Glu27Gln)
One study in BREATHE described tight linkage disequilibrium by not observing any individuals with the compound diplotype of Arg16Arg and Glu27Glu. 49 
Adults (five studies)
A RCT (n = 87) described that LABA response in the context of this genetic variant was age-dependent. 27Gln patients with asthma (≤50 years) had better response to LABA with low and moderate doses of ICS, whereas 27Glu patients (>50 years) were more likely to respond to LABA and ICS combination therapy. 32 Younger 27Gln
carriers responded better to ICS and LABA, and this may be used in personalized asthma treatment. On the other hand, three RCTs comparing Gln27Glu, Gln27Gln, and Glu27Glu (n = 791) did not find any associations focusing on lung function outcomes such as FEV1, FEV1% predicted, FEV1/FEC ratio, and a.m. PEF.
34,40,43
A post hoc analysis of a RCT with 183 patients focused on exacerbations and did not find association between rs1042714 and LABA response. 43 Two studies, of which one was prospective, did not find a pharmacogenetic effect of rs1042714 in LABA response heterogeneity (n = 883) with asthma symptom scores as their main outcome.
40,43
Pediatrics (two studies)
Two studies (n = 643) focused on exacerbations and rs1042714 variance in LABA response heterogeneity, but did not find any differences.
35,49
To summarize results for ADRB2 rs1042714, 1 adult study (n = 87) showed an age-dependent effect. The other five studies did not report any influence of variety in LABA response by rs1042714, but did not assess the effect of age.
| ADRB2 rs1800888 (three studies)
One observational study reported that non-Hispanic white adults with asthma treated with LABA carrying Thr164Ile (n = 18) needed more urgent outpatient health care or emergency department visits for asthma exacerbations during the past year compared to Two RCTs (a post hoc and a genotype-stratified analysis, n = 544 and 183 adults) studied lung function, but did not find any association between Thr164Ile and poor LABA response. 40, 43 To conclude, only adults were studied. It remains inconclusive whether ADRB2 rs1800888 is associated with LABA response.
During LABA treatment, the relationship between lung function and rs1800888 seems to be different compared to the relationship between rs1800888 and exacerbations. Future research on Thr164Ile
and LABA response should include outcome measures in all previously described outcome categories.
| Genetic association and candidate-gene studies with other ADRB2 SNPs (three studies)
Various other SNPs within the ADRB2 gene were investigated in adults (Tables 2 and Table S1 ), but there was no evidence for a pharmacogenetic effect on lung function response to salmeterol. 40 
| ADCY9 (one study)
The ADCY9 gene has been positively associated with LABA response in a post hoc analysis of a 12-week clinical trial (n = 86 Korean adults) using lung function to measure LABA response. After a 2-week "run-in" period, patients received budesonide and formoterol. The following SNPs in ADCY9 were studied: rs2230739 (Ile772Met), rs1045475, rs1045476, rs879619, and rs710893. Two were associated with LABA response.
The ADCY9 rs2230739 Ile772Met was described to be associated with improvement in predicted FEV1: 0.7 ± 9.6 after 8 weeks of treatment (P = 0.03). The ADCY9 rs879619 C/T polymorphism was associated with differences in percent change in MMEF: 7.5 ± 15 (P = 0.016) after 8 weeks of treatment. Nevertheless, these changes are not clinically relevant and did not remain significant after a 12-week follow-up. 37 This study also described a gene-gene interaction of ADCY9
Ile772Met and ADRB2 Arg16Gly. There was a significant FEV1% improvement (8.4 ± 7.5%) in the CT or CC Ile772Met-A/G Gly16Gly genotype combination compared to the TT Ile772Met-A/G or G/G genotype combination. This interaction showed an additive effect on bronchodilator response to LABA in combination therapy. 37 These findings have not been further studied.
| Quality of reporting
Results of the quality reporting assessment can be found in Supplementary Information E2. Eighteen (54.5%) studies were published according to the STREGA guidelines. Restriction of analysis to high-quality papers did not change initial conclusions.
| D ISCUSS I ON
This systematic review showed that most LABA pharmacogenetics studies focused on variants in the ADRB2 gene and that findings differ between adults and children. One variant within that gene and the rs1042713 variant are expected to be associated with LABA-altered response in children, but not in adults. In children, exacerbations were used as main outcome, whereas in adults mainly lung function. Only three studies measured exacerbations as an outcome in adults, but none found association between rs1042713 and LABA response.
Compared to adults, contribution of genetics to variability in LABA response is larger in children with asthma. This could be due to the different phenotype in children, which is often characterized by less airway wall rigidity, more atopy, and shorter exposure to chronic airway inflammation. 55 Also shortened response and airway smooth muscle relaxation time in children and faster maximal bronchoconstriction postexercise are characteristics that differ from adults. 56 These differences underline that children should not just be considered "small adults". 57 Another reason for not observing an effect in adults may be that studies with children have considerable higher numbers compared to the studies conducted in adults. The effect size of ADRB2 SNP effects is small as is the sample size in adults.
In relation to LABA response, it is important to consider that LABA can cause desensitization or downregulation of the B2AR in human bronchial smooth muscle tissue over time. This may result in a decrease in receptors or an increase in receptor degradation. 35 Desensitization and downregulation result in reduced bronchoprotective effects of LABA. 55 Previous studies showed bronchoprotective subsensitivity for LABA in Arg16 homozygous adults. 35, 38, 44 This effect is also seen in children, but has not been studied in relation to their genotypes. 58 ICS can play a role: ICS can reverse functional desensitization of B2ARs and increase receptor expression and density. 56, 59, 60 Loss of bronchoprotection due to regularly inhaled LABA seems to reverse only with high-dose ICS. 61, 62 Only two of the included studies mentioned this mechanism in their discussion as a possible reason for not measuring any effects. 9, 35 The LARGE trial showed no differences between genotypes in PEFR response, but methacholine responsiveness improved in homozygous Gly27 patients treated with salmeterol compared to Arg16 homozygotes.
This finding could highlight differences in desensitization of bronchoprotective effects between polymorphic variants. 9 Few studies focused on the additive or synergic effect of multiple variants on LABA response. Only four studies (study populations 97-639 patients) focused on ADRB2 haplotypes. 35, 39, 40, 43 This did not lead into new insights. Gene-gene interactions with the Arg16Gly were only shown in two studies. A gene-gene interaction was described in a Korean study: FEV1% improvement in the C/T or C/C Ile772Met and A/A genotype of the ADRB2 Arg16Gly was found, but not in the T/T Ile772Met and A/G or G/G Arg16Gly genotype combination. 37 The construction of a genetic risk score might provide more information than focusing on a single SNP. 63 In Caucasian populations, promotor polymorphisms and rs1042714 Glu27Gln were in complete linkage disequilibrium with the Arg16 variant. 49, 64 Glu27Gln haplotypes were confounded by tight disequilibrium with Arg16 variants, and therefore, independent effects were difficult to assess. spectively, and it is a very common allele. 67 On the contrary, Thr164Ile
is very rare (minor allele frequencies: 0.02, 0.00, and 0.00 in European, African, and East Asian healthy controls, respectively). 68 Furthermore, reporting ethnicity is important as unrecognized population stratification can lead to false-positive or false-negative associations. 69 For example, a rare insertion in African Americans treated with LABA leads to increased exacerbations. 54 We recommend new studies to report whether genetic associations with LABA were related to specific ethnicities. A lack of power can also lead to false-negative association. More than half of the included studies did not perform It would even be more beneficial to standardize response definitions in pharmacogenetics or to define composite scores.
To move from association to implementation in clinical practice, clinical validity of identified genetic variants should be assessed. To provide indications about clinical validity, measures such as number needed to genotype, population attributable fraction (proportion of adverse events that can potentially be eliminated if patients carrying the genetic variant receive different treatments), positive and negative predictive value (probability of an adverse event when the genetic variant is present, and probability of no adverse events when the genetic variant is absent), and number needed to treat should be presented. 71 The identified pharmacogenetics studies only provide association measures such as OR and RR. This makes interpretation of the results for use in clinical practice difficult.
We used STREGA to assess the quality of the studies used in this systematic review. With this quality reporting checklist, we objectively assessed quality of reporting in genetic research reports. We recommend future researchers in this field to follow the latest quality guidelines to support validation and replication.
Furthermore, in most studies, patients heterozygous for the associated variant were not included, making it more difficult to translate outcomes into treatment guidelines for all patients with asthma.
In conclusion, there is considerable variability in pharmacogenetic LABA studies due to differences in study design and char- 
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